Key points are not available for this paper at this time.
Introduction: Similar to left ventricular (LV) fibrosis, growing evidence suggests a potential link between right ventricular (RV) fibrosis, poor function of the pressure-overloaded RV, and mortality in patients with pulmonary arterial hypertension (PAH). However, no therapies are currently available that specifically target RV fibrosis. Although the pathological roles of an oxidative stress-sensitive tyrosine kinase c-Src in LV hypertrophy and failure are well characterized, it remains unclear whether c-Src is involved in RV pathology under PAH. Using heterologous expression systems, we previously showed that mitofusin 2 (Mfn2), a key component of the tethering structures between the endoplasmic reticulum (ER) and mitochondria (Mito) is a novel c-Src substrate in mitochondria; and c-Src-dependent tyrosine phosphorylation (P-Tyr) of Mfn2 at the outer mitochondrial membrane (OMM) decreases the ER-Mito distance, possibly through conformational changes of Mfn2, which facilitates ER-to-Mito Ca 2+ transfer and increases reactive oxygen species (ROS). Hypothesis: c-Src signaling alters the size of ER-Mito microdomains and enhances oxidative stress in the RV during PAH. Methods: Primary adult cardiac fibroblasts (CFs) from human ventricles and a preclinical rat PAH model induced by Su gen 5416 injection and 3-week h ypo x ia followed by 4-week normoxia (SuHx) were used for in vitro and in vivo assays, respectively. RV tissues from pulmonary hypertension (PH) patients and sex-/aged-matched controls were used for biochemical and cell biological assays. Results: c-Src activation occurred specifically in CFs in the RV, but not in RV myocytes in a rat SuHx PAH model and human PH-RVs as assessed by immunohistochemistry, which is notably different from the reports on LV hypertrophy and failure. P-Tyr of Mfn2 was detectable from human PH-RVs by Western Blots. RV-CFs from PAH rats exhibited increased c-Src activity, decreased ER-Mito distance, increased ROS, and proliferative signaling activation compared to RV-CFs from control rats as assessed by live cell imaging, immunocytochemistry, and transmission electron microscopy. All of these changes in rat CFs from PAH-RVs were recapitulated by overexpressing c-Src in human CFs in vitro. In addition, c-Src significantly increased the speed and amount of mitochondrial Ca 2+ uptake without changing cytosolic Ca 2+ dynamics in human CFs, suggesting a potential link between c-Src activation, the size of ER-Mito microdomains, and RV fibrosis under PAH. To further dissect the role of c-Src activity in CFs especially in the mitochondria, we specifically inhibited c-Src activity at the OMM, where Mfn2 is located, using an OMM-targeted dominant-negative c-Src (termed mt-c-Src-DN) that was generated by the addition of an OMM-targeting sequence (amino acid 1-33 from human TOM20) to the N-terminus of kinase-dead c-Src-K295R/Y527F. The introduction of mt-c-Src-DN increased the ER-Mito distance and reduced the speed of ER-to-Mito Ca 2+ transport in human CFs. Conclusion: c-Src-dependent P-Tyr of Mfn2 alters the ER-Mito tethering structure, facilitates ER-to-Mito Ca 2+ transport, and increases mitochondrial ROS generation, which promotes CF activation in PAH. Therefore, CF- and mitochondria-specific inhibition of c-Src may provide an additional therapeutic strategy to attenuate RV fibrosis and failure in response to PAH. NIH R01HL136757 (to J.O.-U.), R01HL160699 (to B.S.J.), P30GM1114750 (Targeted project to J.O.-U.), P30GM110759 (Targeted project to J.O.-U.), U54GM115677 (Targeted project to B.S.J.), and American Heart Association (AHA) 18CDA34110091 (to B.S.J.). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Jhun et al. (Wed,) studied this question.